BLOOD RESEARCH

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level

Background: MYC/BCL2 double expression (DE) is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). This study aimed to determine whether the addition of DE to the National Comprehensive Cancer Network Internal Prognostic Index (NCCN-IPI) could improve the prediction of disease progression in patients with DLBCL treated with R-CHOP.Methods: This confirmatory prognostic factor study retrospectively recruited patients with newly diagnosed DLBCL between January 1, 2014, a...

Blood Res 2024; 59:2

Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma

Background: Although most studies on the cardiovascular toxicity of proteasome inhibitors have focused on carfilzomib, the risk of cardiotoxicity associated with bortezomib remains controversial. This study aimed to evaluate the incidence and risk factors of cardiovascular adverse events (CVAEs) associated with bortezomib in patients with multiple myeloma in a real-world setting.Methods: This cross-sectional study included patients who were treated with bortezomib at a tertiary hospital in South Korea. CVAEs, defined as hypertension, arrhythmia, heart failure, myocardial infarction, pulmonar...

Blood Res 2024; 59:3

Upregulation of lnc-FOXD2-AS1, CDC45, and CDK1 in patients with primary non-M3 AML is associated with a worse prognosis

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with an unfavorable outcome. The present research aimed to identify novel biological targets for AML diagnosis and treatment. In this study, we performed an in-silico method to identify antisense RNAs (AS-RNAs) and their related co-expression genes. GSE68172 was selected from the AML database of the Gene Expression Omnibus and compared using the GEO2R tool to find DEGs. Antisense RNAs were selected from all the genes that had significant expression and a survival plot was drawn for them in the GEPIA database, FOXD2-AS1 was ...

Blood Res 2024; 59:4

Comparable outcomes with low-dose and standard-dose horse anti-thymocyte globulin in the treatment of severe aplastic anemia

Background: The standard dose (SD) of horse anti-thymocyte globulin (hATG) ATGAM (Pfizer, USA) or its biosimilar thymogam (Bharat Serum, India) for the treatment of Aplastic Anemia (AA) is 40 mg/kg/day for 4 days in combination with cyclosporine. Data on the impact of hATG dose on long-term outcomes are limited. Here, we describe our comparative experience using 25 mg/kg/day (low-dose [LD]) hATG for 4 days with SD for the treatment of AA. Methods: We retrospectively studied patients with AA (age > 12 years) who received two doses of hATG combined with cyclosporine. Among 93 AA patients who r...

Blood Res 2024; 59:6

Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A: correlation with â��Inhibitorâ�� formation

Background: Development of antibodies against infused Factor VIII (FVIII) or "inhibitors" represents a major challenge following FVIII replacement therapy in patients with hemophilia A (HA). Recent studies have shown that certain cellular compartments of the immune system contribute to the production of such antibodies. Herein, we determined the frequency of class-switched CD19+IgD−CD27+/non-class-switched CD19+IgD+CD27+ memory B cell subsets and CD19+CD27hiCD38hi plasmablasts in patients with severe HA and their association with the development of inhibitors in these patients. Methods:...

Blood Res 2024; 59:16

Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis

Background: Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by reduced factor VIII (FVIII) levels. Approximately 10–15% of patients with severe HA (SHA) do not present with the anticipated bleeding pattern. Here, we assessed the phenotypic severity of hemophilia A using rotational thromboelastometry (ROTEM) and activated partial thromboplastin time-clot waveform analysis (APTT-CWA). Methods: Patients diagnosed with hemophilia A were enrolled. Clinical phenotype assignment was performed according to the published literature, and patients were classified into four phe...

Blood Res 2024; 59:19

Current Issue

Volume 59
2024
View Archives Current Issue
RESEARCH
Prognostic significance and biological implications of SM-like genes in mantle cell lymphoma

Xue He, Changjian Yan, Yaru Yang, Weijia Wang, Xiaoni Liu, Chaoling Wu, Zimu Zhou, Xin Huang, Wei Fu, Jing Hu, Ping Yang, Jing Wang, Mingxia Zhu, Yan Liu, Wei Zhang, Shaoxiang Li, Gehong Dong, Xiaoliang Yuan, Yuansheng Lin, Hongmei Jing and Weilong Zhang

Blood Res (2024) 59:33

Cite Share
RESEARCH
Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status: a single-center database analysis

Soo Young Kang, Heejoo Ko, Raeseok Lee, Sung-Soo Park and Seunghoon Han

Blood Res (2024) 59:31

Cite Share
RESEARCH
Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization

Valentina Perrone, Melania Leogrande, Maria Cappuccilli and Luca Degli Esposti

Blood Res (2024) 59:30

Cite Share

MORE

Review Highlights

REVIEW
Monoclonal gammopathy of renal significance from the perspective of nephrologists

Kootae Park and Soon Hyo Kwon

Blood Res (2024) 59:28

Cite Share
REVIEW
Functional iron deficiency anemia in patients with cancer

Jeong Suk Koh and Ik‑Chan Song

Blood Res (2024) 59:26

Cite Share
REVIEW
Proper application of anticoagulation therapy on cancer-associated venous thrombosis

Ho‑Young Yhim1*

Blood Res (2024) 59:25

Cite Share
REVIEW
Transfusion-transmitted infections

Han Joo Kim and Dae‑Hyun Ko

Blood Res (2024) 59:14

Cite Share

MORE

Most Cited

Review Article
FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs

Jae-Sook Ahn, Hyeoung-Joon Kim

Blood Res 2022; 57(S1): S32-S36

PMC Cite Share
Review Article
Basic immunohistochemistry for lymphoma diagnosis

Junhun Cho

Blood Res 2022; 57(S1): S55-S61

PMC Cite Share
Review Article
Overview of inherited bone marrow failure syndromes

Meerim Park

Blood Res 2022; 57(S1): S49-S54

PMC Cite Share
Review Article
Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Young Hoon Park, Dae-Young Kim, Seongkoo Kim, Young Bae Choi, Dong-Yeop Shin, Jin Seok Kim, Won Sik Lee, Yeung-Chul Mun, Jun Ho Jang, Jong Wook Lee, Hoon Kook, on behalf of Korean Aplastic Anemia Working Party

Blood Res 2022; 57(1): 20-28

PMC Cite Share

MORE

Review Article
Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Young Hoon Park, Dae-Young Kim, Seongkoo Kim, Young Bae Choi, Dong-Yeop Shin, Jin Seok Kim, Won Sik Lee, Yeung-Chul Mun, Jun Ho Jang, Jong Wook Lee, Hoon Kook, on behalf of Korean Aplastic Anemia Working Party

Blood Res 2022; 57(1): 20-28

PMC Cite Share
Review Article
Diagnosis and management of thrombocytopenia in pregnancy

Young Hoon Park

Blood Res 2022; 57(S1): S79-S85

PMC Cite Share
Review Article
Update on primary plasma cell leukemia

Sung-Hoon Jung, Je-Jung Lee

Blood Res 2022; 57(S1): S62-S66

PMC Cite Share
Review Article
Basic immunohistochemistry for lymphoma diagnosis

Junhun Cho

Blood Res 2022; 57(S1): S55-S61

PMC Cite Share

MORE

Aims and Scope

Blood Research is a peer-reviewed open-access journal that delivers significant clinical, translational and basic study results in hematology and related fields to readers worldwide. Blood Research presents coverage on topics from basic laboratory research to clinical studies, translational studies, and precision medicine in the field of hematology. Any physicians or researchers throughout the world are welcome to submit a manuscript related to topics in hematology written in English.

All the submitted manuscripts undergo intensive peer review by at least two independent reviewers. They are selected based on the importance of the topic, originality of the work, quality of the content, and compliance with the journal's format.

2.3

Current Issue

Prognostic significance and biological implications of SM-like genes in mantle cell lymphoma

Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status: a single-center database analysis

Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization

Review Highlights

Monoclonal gammopathy of renal significance from the perspective of nephrologists

Functional iron deficiency anemia in patients with cancer

Proper application of anticoagulation therapy on cancer-associated venous thrombosis

Transfusion-transmitted infections

Most Cited

FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs

Basic immunohistochemistry for lymphoma diagnosis

Overview of inherited bone marrow failure syndromes

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Diagnosis and management of thrombocytopenia in pregnancy

Update on primary plasma cell leukemia

Basic immunohistochemistry for lymphoma diagnosis

Aims and Scope

Editorial Office

2.3

Current Issue

Review Highlights

Most Cited

Most Read

Aims and Scope

Editorial Office